Anavex Life Sciences Corp.
AVXL· Nasdaq
AVXLAnavex Life Sciences Corp.
Filed Feb 7, 2024 · 10-Q · 38 days after period end · 0001731122-24-000206
| Metric | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|
| Net Income | -$8.62M | -$12.97M | -$10.88M | -$7.86M |
| EPS Diluted | -$0.11 | -$0.17 | -$0.14 | -$0.12 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Anavex Life Sciences Corp. · CIK 1314052 · Engraved from SEC EDGAR
ended Dec 31, 2023 · filed Feb 7, 2024 · 38 d after period end
